Archive for the ‘Stem Cell Medicine’ Category

Stem Cell Therapy NYC, Regenerative Medicine Injections …

Stem Cell Medicine | Posted by admin
Jul 11 2018

Brooklyn NYC 2279 Coney Island Ave, #100 Brooklyn, NY 11223

Manhattan NYC 234 East 23 Street, Ste 1 New York, NY 10010

* Immediate lab & testing results * Same day appointments

Advanced Regenerative Medicine Center Of New York

How Stem Cells help in Sports Injuries

Platelet rich plasma therapy

Joint regeneration therapy

Stem cell doctor Reyfman offers the most effective stem cell treatments available in the USA. Come see our new cutting edge, state-of-the-art regenerative medicine clinic in NYC.

Stem cell knee therapy is a proven, effective treatment for injuries and diseases…

Hip injuries and ailments can be debilitating. Stem cell therapy for hips…

Your spine is a complex network of bones, tendons, ligaments, muscles…

Shoulder therapy, particularly physical therapy, can put you out of commission…

If you suffer an injury or ailment to your foot or ankle, you lose not only mobility…

Medical treatments using stem cells have shown dramatic results and…

Board-Certified Pain Management Physician who specializes in the treatment of athletic injuries and chronic conditions including artritis pain using the cutting edge stem cell injections and regenerative medicine procedures.

For more information about the the stem cell therapy treatment for knee, ankle, hip, back or shoulder pain offered at Stem Cell Therapy Brooklyn or to schedule a consultation with the with the stem cell doctor, Dr. Leon Reyfman, please contact our NYC pain management clinic in Manhattan, Brooklyn & Queens.

All I can say is WOW thank God I found this place! Ive worked at a desk for 60 hours a week for the past 10 years, and it really started to take a toll on my back just this year. Through a good recommendation from a buddy of mine, I went to go see Dr. Reyfman and I am finally starting to be able to sleep at night again. Best pain management doctor. Bravo stem cell Dr. Reyfman! ~Yelp

Stem cell therapy NYC specialist Dr. Leon Reyfman and his team of pain relief specialists with locations in Manhattan, Brooklyn and Queens have always believed that the least invasive tactics for relieving pain are the most beneficial. When you visit stem cell doctor Reyfman in his NYC regenerative medicine clinic, youre treated with respect and concern. If youre in pain, its Dr. Leon Reyfmans job to relieve it.

This regenerative therapy is widely becoming recognized and accepted throughout the traditional medical community as a first line of defense against chronic pain. Stem cell treatments rely on your own stem cells removed from your bone marrow and injected into the areas that are causing you pain. Theres no need to tread into the controversial field of embryonic stem cell cultivation when you carry all the necessary tools within your own body to heal yourself.

When you visit the Brooklyn, Queens or NYC office, you never receive cookie-cutter treatment. Following a thorough medical history and a complete examination that may include blood work and X-rays, stem cell doctor Leon Reyfman spends time getting to know you, your medical goals and your willingness to try innovative procedures, such as stem cell therapy.

As an interventional pain management specialist with years of experience in NYC, stem cell Dr. Leon Reyfman and his team have relied on traditional methods of pain management. But now we offer stem cell therapy treatment and regenerative therapy for many painful chronic conditions including Shoulder Arthritis, Tendonitis, Chronic Neck Pain, Chronic Back Pain, Hip Arthritis, Arthritis of the Knee or Ankle.

Additionally, platelet rich plasma treatments rely on your own healthy blood cells to stir recovery of diseased and damaged areas of your body. A simple centrifuge spins platelets out of your blood so that they can be injected directly into the places that need a greater blood supply.

Stem Cell Therapy & Regenerative Medicine of Brooklyn NY: 2279 Coney Island Ave, 2nd Fl, Brooklyn, NY 11223 | Tel: (718) 488-0188

Stem Cell Therapy & Regenerative Medicine of Manhattan NYC: 234 East 23 Street, Ste 1, New York, NY 10010 | Tel: (212) 612-2222

Stem Cell Therapy & Regenerative Medicine of Queens NY: 96-18 63 Drive, Ste 202, Rego Park, NY 11374 | Tel: (718) 459-9999

We were selected to be a part of international medical team for Rio Olympic Games

2017 Stem Cell Therapy Brooklyn, Queens, Manhattan NYC. All Rights Reserved. Privacy Policy

Website & Management by NYMM

Read the original:
Stem Cell Therapy NYC, Regenerative Medicine Injections …

Stem Cell Therapy San Antonio TX | Alternative …

Stem Cell Medicine | Posted by admin
Oct 12 2017

Injury Assessment

Do you suffer from pain in your back or your joints, such as hip or knee, which prevents you from living life to the fullest? Is walking, cycling, gardening, fishing, or exercising, no longer possible with out pain? If you are missing out on your Golden Years, you need to see a regenerative medicine physician for a consultation. They can determine if the newest innovations in stem cell therapies are right for you.

The treatment is a simple non-surgical injection into the affected joint with no down time or lengthy recovery. You may maintain your normal lifestyle and allow the cells to create a balanced optimal environment in your joints so your body can repair itself. You should feel maximal results within 10 to 12 weeks at which time you can increase your activity levels to match your comfort, but understand that the regenerative process can continue for long periods of time.

Umbilical cord cells contain growth factors, proteins, and stem cells that continue to produce additional growth factors and proteins for a period of time. These components have the potential to positively affect the environment inside the joint and to stimulate your own tissue to aid in the regenerative process while ALSO stimulating your NATIVE STEM CELLS to aid in regeneration.

Continue reading here:
Stem Cell Therapy San Antonio TX | Alternative …

Human skin cells transformed directly into motor neurons – Washington University School of Medicine in St. Louis

Stem Cell Medicine | Posted by admin
Sep 08 2017

Visit the News Hub

New technique could aid treatments for diseases that lead to paralysis

Scientists have discovered a new way to convert human skin cells directly into motor neurons (above). The technique, developed at Washington University School of Medicine in St. Louis, could help researchers better understand diseases of motor neurons, such as amyotrophic lateral sclerosis. Human motor neurons are difficult to study since they can’t be taken from living patients. The motor neurons pictured were converted from skin cells sampled from a healthy 42-year-old woman.

Scientists working to develop new treatments for neurodegenerative diseases have been stymied by the inability to grow human motor neurons in the lab. Motor neurons drive muscle contractions, and their damage underlies devastating diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy, both of which ultimately lead to paralysis and early death.

In new research, scientists at Washington University School of Medicine in St. Louis have converted skin cells from healthy adults directly into motor neurons without going through a stem cell state.

The technique makes it possible to study motor neurons of the human central nervous system in the lab. Unlike commonly studied mouse motor neurons, human motor neurons growing in the lab would be a new tool since researchers cant take samples of these neurons from living people but can easily take skin samples.

The study is published Sept. 7 in the journal Cell Stem Cell.

Avoiding the stem cell phase eliminates ethical concerns raised when producing what are called pluripotent stem cells, which are similar to embryonic stem cells in their ability to become all adult cell types. And importantly, avoiding a stem cell state allows the resulting motor neurons to retain the age of the original skin cells and, therefore, the age of the patient. Maintaining the chronological age of these cells is vital when studying neurodegenerative diseases that develop in people at different ages and worsen over decades.

In this study, we only used skin cells from healthy adults ranging in age from early 20s to late 60s, said senior author Andrew S. Yoo, PhD, an assistant professor of developmental biology. Our research revealed how small RNA molecules can work with other cell signals called transcription factors to generate specific types of neurons, in this case motor neurons. In the future, we would like to study skin cells from patients with disorders of motor neurons. Our conversion process should model late-onset aspects of the disease using neurons derived from patients with the condition.

Going back through a pluripotent stem cell phase is a bit like demolishing a house and building a new one from the ground up, Yoo said. What were doing is more like renovation. We change the interior but leave the original structure, which retains the characteristics of the aging adult neurons that we want to study.

The ability of scientists to convert human skin cells into other cell types, such as neurons, has the potential to enhance understanding of disease and lead to finding new ways to heal damaged tissues and organs, a field called regenerative medicine.

Human skin cells (above) sampled from a healthy adult and then converted into different types of neurons have the potential to be a valuable research tool. Similar skin samples from patients with neurodegenerative diseases could allow scientists to study the disease in its native cell type.

To convert skin cells into motor neurons, the researchers exposed the skin cells to molecular signals that are usually present at high levels in the brain. Past work by Yoo and his colleagues then at Stanford University showed that exposure to two short snippets of RNA turned human skin cells into neurons. These two microRNAs called miR-9 and miR-124 are involved with repackaging the genetic instructions of the cell.

In the new study, the researchers extensively characterized this repackaging process, detailing how skin cells reprogrammed into generic neurons then can be guided into specific types of neurons. They found that genes involved in this process become poised for expression but remain inactive until the correct combination of molecules is provided. After much experimentation with multiple combinations, the researchers found that adding two more signals to the mix transcription factors called ISL1 and LHX3 turned the skin cells into spinal cord motor neurons in about 30 days.

The combination of signals microRNAs miR-9 and miR-124 plus transcription factors ISL1 and LHX3 tells the cell to fold up the genetic instructions for making skin and unfurl the instructions for making motor neurons, according to Yoo and the studys co-first authors, Daniel G. Abernathy and Matthew J. McCoy, doctoral students in Yoos lab; and Woo Kyung Kim, PhD, a postdoctoral research associate.

Another past study from Yoos team showed that exposure to the same two microRNAs, miR-9 and miR-124, plus a different mix of transcription factors could turn skin cells into a different type of neuron. In that case, the skin cells became striatal medium spiny neurons, which are affected in Huntingtons disease an inherited, eventually fatal genetic disorder that causes involuntary muscle movements and cognitive decline beginning in middle adulthood.

In the new study, the researchers said the converted motor neurons compared favorably to normal mouse motor neurons, in terms of the genes that are turned on and off and how they function. But the scientists cant be certain these cells are perfect matches for native human motor neurons since its difficult to obtain samples of cultured motor neurons from adult individuals. Future work studying neuron samples donated from patients after death is required to determine how precisely these cells mimic native human motor neurons.

This work is supported by the National Institutes of Health (NIH) Directors Innovator Award, grant number DP2NS083372-01; the Presidential Early Career Award for Scientists and Engineers; the Missouri Spinal Cord Injury/Disease Research Program; the Cure Alzheimers Fund; Andrew B. and Virginia C. Craig Faculty Fellowship; a Philip and Sima Needleman Graduate Student Fellowship; a Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Fellowship, grant number T32GM081739; and the Childrens Discovery Institute.

Abernathy DG, Kim WK, McCoy MJ, Lake AM, Ouwenga R, Lee SW, Xing X, Li D, Lee HJ, Heuckeroth RO, Dougherty JD, Wang T, Yoo AS. MicroRNAs induce a permissive chromatin environment that enables neuronal subtype-specific reprogramming of adult human fibroblasts. Cell Stem Cell. Sept. 7, 2017.

Washington University School of Medicines 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more:
Human skin cells transformed directly into motor neurons – Washington University School of Medicine in St. Louis

Cambridge Enterprise and Qkine to drive stem cell and regenerative medicine research – Business Weekly

Stem Cell Medicine | Posted by admin
Sep 02 2017

Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and specialist growth factor manufacturer Qkine Ltd have signed a key licensing deal for Activin A production technology.

Qkine is a recent spin-out from the university. The newly-licensed methodology, which was developed by one of the companys founders Dr Marko Hyvnen, will be used to manufacture proteins utilised for control of stem cell growth and differentiation.

Growth factors are proteins that transmit signals from one cell to another in higher organisms, orchestrating organisation of the developing embryo and regulating biological functions and repair processes in adults. Activin A, and others from its family of proteins, are essential ingredients used by stem cell scientists to mimic the environment in the human body. They allow carefully synchronised messages to be sent to stem cells, effectively telling them to turn into the desired cell type.

With exponential growth in the study of stem cells for disease modelling, drug screening, precision medicine and development of new therapeutics the need for high quality reagents for fine control of stem cell cultures is ever increasing.

Growing demand for Activin A and related growth factors and an opportunity to use protein engineering techniques to optimise these growth factors motivated Hyvnen and co-founder Dr Catherine Onley, a translational scientist, to start Qkine. Its mission is to produce high quality bioactive proteins for stem cell researchers and the regenerative medicine industry.

Hyvnen said: I have been providing growth factors to the Cambridge stem cell community for almost a decade.

Demand is growing from labs outside Cambridge and forming Qkine will allow us to focus on producing the highest quality cytokines for these scientists and establish a unique UK-based supplier of one of the enabling technologies for regenerative medicine, one of the priority areas for British manufacturing recently identified by the Government.

Qkine co-founders Dr Marko Hyvnen (picture courtesy – Chris Green) and Dr Catherine Onley (picture courtesy Suzi Ovens)

Qkine was awarded a Cambridge Enterprise Pathfinder investment in December 2016 to facilitate the founding of the company. Qkine started operation as an embedded company at the Department of Biochemistry in April 2017.

Dr Iain Thomas, head of Life Sciences at Cambridge Enterprise, said: Qkine is a great example of how opportunities are incubated in the University until the commercial time is right.

We are delighted that Qkine is taking this technology into the stem cell and regenerative medicine markets both of which are important and rapidly growing.

Continued here:
Cambridge Enterprise and Qkine to drive stem cell and regenerative medicine research – Business Weekly

Six Japanese arrested over medical treatments using blood taken from umbilical cords, which are popular with Chinese … – South China Morning Post

Stem Cell Medicine | Posted by admin
Sep 01 2017

Six people have been arrested in Japan over the illegal sale and use of blood from umbilical cords and placenta in regenerative medical treatments, with Chinese nationals reportedly the biggest foreign clients of clinics carrying out the procedures.

Police have referred Tsuneo Shinozaki, the head of a company that brokered the illegal sale of cord blood, to prosecutors, along with the head of a Tokyo regenerative medicine clinic and four others. The doctor has also been charged with breaking the law on regenerative medicine.

Blood taken from umbilical cords and placenta is high in blood-forming stem cells, which are used in treatments for leukaemia and other critical diseases. There are also hopes that research into regenerative medicine will find cures to cardiac and other complaints, and may even mitigate the effects of Parkinsons disease by implanting nerve cells into the brain.

Chinese people misunderstand stem cell treatments and they just see it as some sort of magic solution

Manager of a Tokyo clinic

There are, however, elevated risks of infection and graft rejection, meaning any procedures using cord blood require extensive testing to ensure compatibility and explicit authorisation from Japans health ministry.

Claims the blood is also an effective beauty treatment have not been proven but that has not put off more than 1,000 patients undergoing such procedures at facilities across Japan in recent years. It has also been claimed it is effective in treating cancer, although that suggestion also remains unproven to date.

The manager of a clinic in Kyoto told local media Chinese people who had learnt of regenerative therapies had travelled to Japan on organised medical tourism trips.

Chinese people misunderstand stem cell treatments and they just see it as some sort of magic solution to any health problems that they have, the manager of a Tokyo-based clinic told the South China Morning Post.

They come to Japan because this sort of treatment is not available in China and because Japan is seen as being advanced in this area and having good medical facilities, said the official, who declined to be named and insisted his facility did not conduct procedures using umbilical cord blood.

He added that, under Japanese law, clinics are limited in the services they are able to advertise on their websites, but some clinics take out advertisements in China through other companies, enabling them to evade scrutiny.

It is not illegal for Chinese people to travel abroad for medical procedures, including regenerative therapies.

According to investigators, illegal injections of umbilical cord blood were conducted at clinics and private hospitals in at least 20 prefectures across Japan, with about 30 per cent of the clients from overseas.

Facilities charged between 3 million yen (HK$212,500) and 4 million yen for each injection.

By law, umbilical cord blood is donated free of charge to publicly operated blood banks by women after they have given birth. The blood is kept in storage. Such banks have to be licensed and are closely regulated to ensure safety.

The blood used in the recent unmonitored treatments was obtained from a blood bank that went bankrupt. Brokers paid to obtain the blood and sold it on to clinics.

Excerpt from:
Six Japanese arrested over medical treatments using blood taken from umbilical cords, which are popular with Chinese … – South China Morning Post

FDA announces actions regarding stem cell treatments – Lexology (registration)

Stem Cell Medicine | Posted by admin
Sep 01 2017

Together with new guidance regarding the potential regulatory pathways for gene therapies, the FDA announced on Monday, August 28, 2017, that it will be taking action against companies providing unapproved stem cell treatments. This new guidance, combined with the threat of enforcement actions, provides the regenerative medicine industry and its partners with certain direction regarding the differences between pioneering stem cell therapies for which regulatory pathways are being crafted and unapproved treatments, which are likely to trigger scrutiny by the FDA.

Overview of enforcement actions

On August 24, the FDA issued a warning letter to a Florida clinic that recovered a patient’s own adipose tissues, processed those tissues into stromal vascular fraction (SVF) i.e., adult stem cells derived from the patient’s own fat and then administered the SVF to the patient for treatment of any one of several conditions, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and chronic obstructive pulmonary disease (COPD).

The FDA rejected the clinic’s arguments that

Instead, the FDA took the position that the post-recovery processing of the adipose tissues takes the procedure outside of both the definition of an HCT/P and the same-surgical-procedure exception. The agency further noted that use of SVF for conditions such as Parkinson’s disease, ALS and COPD do not meet the homologous use requirement of 21 CFR 1271.10. The agency also announced an action against a separate stem cell therapy clinic in California.

In light of these developments, practitioners and clinics who are

Guidance for regenerative medicine companies

While announcing these regulatory and enforcement actions, the FDA also sought to reassure the regenerative medicine industry of the agency’s dedication to promoting this field of science. FDA Commissioner Scott Gottlieb wrote that the agency plans to “advance a comprehensive policy framework that will more clearly describe the rules of the road for this new field.” Manifesting the agency’s willingness to work with industry, Dr. Gottlieb noted that while “[m]any of the individualized treatments fall clearly outside the FDA’s pre-market requirements[f]or those that currently fall across the line and are subject to the FDA’s existing pre-market review, we want to make sure the process for gaining FDA approval is efficient. We want to facilitate innovation.” Thus, while signaling its intent to take action against entities it believes are “targeting vulnerable patients,” the FDA indicated that it “will give current product developers a very reasonable period of time to interact with the FDA in order to determine if they need to submit an application for marketing authorization and to come into the agency and work on a path towards approval.”

The FDA also reaffirmed its commitment to fully implementing the regenerative medicine advanced therapy (RMAT) designation process. The designation is given to cell therapies, therapeutic tissue engineering products, human cell and tissue products, or any combination product using such therapies or products intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. See Section 3033 of the 21st Century Cures Act.

These are important developments for stakeholders across the regenerative medicine industry, including:

Read more here:
FDA announces actions regarding stem cell treatments – Lexology (registration)

Human Stem Cells Fight Parkinson’s Disease in Monkeys – Scientific American

Stem Cell Medicine | Posted by admin
Aug 31 2017

LONDON (Reuters)Scientists have successfully used reprogrammed stem cells to restore functioning brain cells in monkeys, raising hopes the technique could be used in future to help patients with Parkinsons disease.

Since Parkinsons is caused by a lack of dopamine made by brain cells, researchers have long hoped to use stem cells to restore normal production of the neurotransmitter chemical.

Now, for the first time, Japanese researchers have shown that human induced pluripotent stem cells (iPS) can be administered safely and effectively to treat primates with symptoms of the debilitating disease.

So-called iPS cells are made by removing mature cells from an individualoften from the skinand reprogramming them to behave like embryonic stem cells. They can then be coaxed into dopamine-producing brain cells.

The scientists from Kyoto University, a world-leader in iPS technology, said their experiment indicated that this approach could potentially be used for the clinical treatment of human patients with Parkinsons.

In addition to boosting dopamine production, the tests showed improved movement in affected monkeys and no tumors in their brains for at least two years.

The human iPS cells used in the experiment worked whether they came from healthy individuals or Parkinsons disease patients, the Japanese team reported in the journal Nature on Wednesday.

This is extremely promising research demonstrating that a safe and highly effective cell therapy for Parkinsons can be produced in the lab, said Tilo Kunath of the MRC Centre for Regenerative Medicine, University of Edinburgh, who was not involved in the research.

The next step will be to test the treatment in a first-in-human clinical trial, which Jun Takahashi of Kyoto University told Reuters he hoped to start by the end of 2018.

Any widespread use of the new therapy is still many years away, but the research has significantly reduced previous uncertainties about iPS-derived cell grafts.

The fact that this research uses iPS cells rather human embryonic stem cells means the treatment would be acceptable in countries such as Ireland and much of Latin America, where embryonic cells are banned.

Excitement about the promise of stem cells has led to hundreds of medical centers springing up around the world claiming to be able to repair damaged tissue in conditions such as multiple sclerosis and Parkinsons.

While some treatments for cancer and skin grafts have been approved by regulators, many other potential therapies are only in early-stage development, prompting a warning last month by health experts about the dangers of stem-cell tourism.

Read more:
Human Stem Cells Fight Parkinson’s Disease in Monkeys – Scientific American

In utero stem cell transplants may replace riskier childhood transplants for multiple conditions – Medical Xpress

Stem Cell Medicine | Posted by admin
Aug 31 2017

August 31, 2017 by Suzanne Leigh Tippi MacKenzie, MD, a pediatric and fetal surgeon at UCSF Benioff Childrens Hospital San Francisco, is the principal investigator for a clinical trial that will use in utero stem cell transplants to treat fetuses with an inherited disorder that restricts the bloods ability to carry oxygen to vital organs. Credit: Cindy Chew

UCSF Benioff Children’s Hospitals in San Francisco and Oakland will pioneer stem cell transplants for a uniquely challenging patient population: second-trimester fetuses stricken with a potentially fatal disease.

The two hospitals are enrolling 10 pregnant women in the first phase of a clinical trial to treat fetuses with an inherited disorder that restricts the blood’s ability to carry oxygen to vital organs. The trial, the first of its kind in the world, is funded by a $12.1 million grant from the California Institute for Regenerative Medicine.

Alpha thalassemia (ATM) affects 5 percent of the world’s population, but is significantly more prevalent in China, Southeast Asia, India and the Middle East parts of the globe where many residents of the San Francisco Bay Area claim their origins. In its most extreme form, alpha thalassemia major (ATM), the condition leads to progressive anemia and heart failure before birth. Standard treatment in the United States includes lifelong blood transfusions.

Stem cell transplants from a matched donor in childhood have proven to be curative in some cases, but patients face risks, including graft-versus-host disease and serious side effects from immune-suppression drugs.

The trial is based on the premise that risks could be minimized by harnessing the “tolerance” between the pregnant woman and fetus before birth, said principal investigator Tippi MacKenzie, MD, a pediatric and fetal surgeon at UCSF Benioff Children’s Hospital San Francisco.

Hope That Procedure Could Be Adopted Worldwide

“In performing the procedure in utero when the fetus’s immune system is underdeveloped, we can avoid the aggressive treatments required for postnatal transplants for children with alpha thalassemia,” MacKenzie said. “Eventually, the procedure may become a treatment option in parts of the world where ATM is most common. Due to lack of treatment possibilities in many countries, most pregnancies are either terminated on diagnosis or result in fetal demise,” she said.

The trial follows a decades-long odyssey marked by triumphs and tribulations for researchers in the field. Fetal transplants using stem cells from other fetuses to treat blood disorders were carried out in the 1980s, but were only marginally successful due to engraftment failure. Researchers around the world searched for answers by turning to animal studies.

‘Eureka Moment’ Spurred Sea Change

“The fetus, unlike a fully developed human, can accept foreign cells, because its immune system is not yet primed to fight bacteria and viruses,” said MacKenzie. “This undeveloped immune system benefits the fetus throughout the pregnancy, because it prevents it from launching an immune response to its mother’s cells that are naturally circulating in its bloodstream.”

Further research led to Mackenzie’s “eureka moment,” when it was discovered that the mother’s immune system is actually responsible for rejecting other cells that are transplanted into the fetus. If the mother’s cells are transplanted, they can engraft without being rejected. “This led to a sea change in our strategy to use maternal cells for the transplants,” she said.

In the trial, bone marrow will be collected from women who are between 18 and 25 weeks pregnant, with a fetal diagnosis of ATM. The bone marrow cells will be processed and hematopoietic cells immature stem cells that can evolve into all types of blood cells will be singled out from the mix. They will then be injected through the woman’s abdomen, into the umbilical vein of the fetus, where they can circulate through the bloodstream, developing into healthy mature blood cells.

The procedure is not without risks to the fetus and the pregnant woman. To minimize risks, the researchers restricted the trial to ATM, since the fetus is already undergoing blood transfusions. “An additional procedure for the transplantation is not necessary, since the maternal stem cells are infused at the same time as an in utero blood transfusion,” said Elliott Vichinsky, MD, director of hematology/oncology at UCSF Benioff Children’s Hospital Oakland, who will head the hematologic management of the fetus and newborn. “This should reduce additional risks to the fetus.” Since the underlying disease causes complications, the woman will be monitored throughout her pregnancy and the fetus will continue to receive blood transfusions until birth.

UCSF is a pioneer in thalassemia research and the birthplace of fetal surgery. UCSF Benioff Children’s Hospital Oakland is home to the Northern California Comprehensive Thalassemia Center, which was established in 1991 and is now the largest such program nationwide, with a focus on caring for patients and leading research into new treatments.

“We are excited about launching this trial, which combines the expertise of UCSF Benioff Children’s Hospitals in San Francisco and Oakland. This study offers families with a usually fatal ATM pregnancy the chance of survival and cure,” said Vichinsky, who founded the Northern California Comprehensive Thalassemia Center.

Treatment May Be Tested for Sickle Cell Anemia

Patient recruitment will continue for five years, during which pregnant women and their babies will be followed after birth for 30 days and one year respectively. If successful, the procedure will be carried out for fetuses with beta thalassemia, a more common and less serious variant of the disorder, as well as sickle cell anemia, in collaboration with Children’s Hospital of Philadelphia. Other conditions requiring stem cell transplants after birth may be considered, said MacKenzie.

The incidence of ATM is unknown because most fetuses with the disorder die before delivery. The condition occurs when both parents are carriers for thalassemia. In places where women have access to prenatal care, ATM is usually suspected on ultrasound and confirmed by DNA analysis in the second trimester.

Explore further: Immune system drives pregnancy complications after fetal surgery in mice

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read this article:
In utero stem cell transplants may replace riskier childhood transplants for multiple conditions – Medical Xpress

Puppies benefit from stem cell treatment for children with spina bifida – University of California

Stem Cell Medicine | Posted by admin
Aug 31 2017

A pair of English bulldog puppies are the first patients to be successfully treated with a unique therapy a combination of surgery and stem cells developed at the University of California, Davis, to help preserve lower-limb function in children with spina bifida.

Because dogs with the birth defect frequently have little control of their hindquarters, they also have little hope for a future. They are typically euthanized as puppies.

At their postsurgery re-check at 4 months old, however, the siblings, named Darla and Spanky, showed off their abilities to walk, run and play to their doctor,veterinary neurosurgeon Beverly Sturges.

The initial results of the surgery are promising, as far as hind limb control, said Sturges. Both dogs seemed to have improved range of motion and control of their limbs.

The dogs have since been adopted, and continue to do well at their home in New Mexico.

Spina bifida occurs when spinal tissue improperly fuses in utero, causing a range of cognitive, mobility, urinary and bowel disabilities in about 1,500 to 2,000 children born in the U.S. each year. The dogs procedure, which involved surgical techniques developed byfetal surgeon Diana Farmerof UC Davis Health together with a cellular treatment developed by stem cell scientistsAijun WangandDori Borjesson, director of the universitysVeterinary Institute for Regenerative Cures, represents a major step toward curing spina bifida for both humans and dogs.

Farmer pioneered the use of surgery prior to birth to improve brain development in children with spina bifida. She later showed that prenatal surgery combined with human placenta-derived mesenchymal stromal cells (PMSCs), held in place with a cellular scaffold, helped research lambs born with the disorder walk without noticeable disability.

Sturges wanted to find out if the surgery-plus-stem-cell approach could give dogs closer-to-normal lives along with better chances of survival and adoption. At 10-weeks old, Darla and Spanky were transported from Southern California Bulldog Rescue to the UC Davis veterinary hospital, where they were the first dogs to receive the treatment, this time using canine instead of human PMSCs.

Another distinction for Darla and Spanky is that their treatment occurred after birth, since prenatal diagnosis of spina bifida is not performed on dogs, Sturges explained. The disorder becomes apparent between 1 and 2 weeks of age, when puppies show hind-end weakness, poor muscle tone, incoordination and abnormal use of their tails.

UC Davis is the only place where this type of cross-disciplinary, transformational medicine could happen, according to Farmer.

Its rare to have a combination of excellent medical and veterinary schools and strong commitment to advancing stem cell science at one institution, she said.

UC Davis is also home to the One Healthinitiative aimed at finding novel treatmentslike thesefor diseases that affect both humans and animals.

Ive often said that I have the greatest job on the planet, because I get to help kids, Farmer said. Now my job is even better, because I get to help puppies too.

With additional evaluation and U.S. Food and Drug Administration approval, Farmer and Wang hope to test the therapy in human clinical trials. Sturges and Borjesson hope to do the same with a canine clinical trial. They hope the outcomes of their work help eradicate spina bifida in dogs and humans.

In the meantime, the team wants dog breeders to send more puppies with spina bifida to UC Davis for treatment and refinements that help the researchers fix an additional hallmark of spina bifida incontinence. While Darla and Spanky are very mobile and doing well on their feet, they still require diapers.

Further analysis of their progress will determine if the surgery improves their incontinence conditions, Sturges said.

Funding for this project was provided by the Veterinary Institute for Regenerative Cures (VIRC) at the UC Davis School of Veterinary Medicine, and the Surgical Bioengineering Lab at the UC Davis School of Medicine. Private donations to the veterinary school for stem cell research also contributed to this procedure. Farmer and Wangs spina bifida research is supported by funding from the National Institutes of Health, the California Institute for Regenerative Medicine, Shriners Hospitals for Children and the March of Dimes Foundation.

Originally posted here:
Puppies benefit from stem cell treatment for children with spina bifida – University of California

Why Doug Baldwin went to England for stem-cell therapy – The News Tribune (blog)

Stem Cell Medicine | Posted by admin
Aug 29 2017

The News Tribune (blog)
Why Doug Baldwin went to England for stemcell therapy
The News Tribune (blog)
RENTON Turns out, Doug Baldwin started this current Seahawks fad of traveling outside the team's normal medical coverage to get far-flung treatment using body cells. The Seahawks' No. 1 wide receiver told me Monday he went overseas before this season …

and more »

Read the rest here:
Why Doug Baldwin went to England for stem-cell therapy – The News Tribune (blog)